Abstract
This study was conducted to characterize the diuretic effect of OPC-41061, a nonpeptide vasopressin V2-receptor antagonist, and furosemide by administering each alone and in combination in conscious male rats. OPC-41061 at 1 and 10 mg/kg and furosemide at 10 and 100 mg/kg dose-dependently increased urine volume to the same extent. The high dose of OPC-41061 (10 mg/kg) markedly elevated electrolyte-free water clearance (E-Ch2 o) to a positive value. In contrast to OPC-41061, furosemide elevated only electrolyte clearance but not E-Ch2 o. The differences in diuretic profile reflected the changes in serum sodium and hormone levels. OPC-41061 dose-dependently elevated serum sodium concentration, but furosemide tended to decrease it. The high dose of furosemide (100 mg/kg) significantly elevated serum renin activity and aldosterone concentration, indicating that furosemide activated the renin-angiotensin-aldosterone system (RAA-system). On the other hand, OPC-41061 did not affect these parameters. When OPC-41061 was administered concomitantly with furosemide, OPC-41061 significantly increased urine volume and E-Ch2 o, and decreased urinary osmolality compared with furosemide alone. OPC-41061 dose-dependently elevated serum osmolality and sodium concentration even when administered in combination with the high dose of furosemide. These results suggest that OPC-41061 produces aquaresis leading to increased serum sodium without affecting the RAA-system. On the other hand, furosemide produced natriuresis, leading to decreased serum sodium level and activation of the RAA-system. It was also demonstrated that OPC-41061 produced an additive diuretic effect and elevated serum sodium level in the presence of furosemide.
Footnotes
-
Send reprint requests to: Takahiro Hirano, Tokushima New Drug Research Institute, Otsuka Pharmaceutical Co. Ltd., 463-10, Kagasuno, Kawauchi-cho, Tokushima 771-0192, Japan. E-mail:t_hirano{at}research.otsuka.co.jp
- Abbreviations:
- AVP
- arginine vasopressin
- E-Ch2 o
- electrolyte-free water clearance
- E-Cosm
- electrolyte clearance
- RAA-system
- renin-angiotensin-aldosterone system
- Received July 19, 1999.
- Accepted September 24, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|